U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. ECI Pharmaceuticals, LLC - 625254 - 03/16/2022
  1. Warning Letters


ECI Pharmaceuticals, LLC MARCS-CMS 625254 —


Recipient Name
John Copanos
ECI Pharmaceuticals, LLC

5311 NW 35th Terrace
Ft. Lauderdale, FL 33309
United States

Issuing Office:
Center for Drug Evaluation and Research | CDER

United States

Mr. Copanos,

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter # 2267. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter and corrected the data deficiencies. Future FDA regulatory activities will further assess the adequacy and sustainability of these corrections. 

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and to continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during additional data review projects, future inspections, or through other means. 

Carolyn E. Becker, J.D. 
Director, Office of Unapproved Drugs & Labeling Compliance
Center for Drug Evaluation and Research Office of Compliance 
U.S. Food and Drug Administration 
Tel: 301-796-8801 

CC: Florida District Office

Back to Top